How does work Imatinib in leukemia?

[medixocentre]

Imatinib attaches to the active site of tyrosine kinase and blocks its activity. Imatinib is the first new substance that inhibits only specific enzymes in specific cancers without killing all rapidly dividing cells in an unspecific manner, and has become an example for other targeted therapies that inhibit tyrosine phosphatase. Clinical results show that 98.15% of patients who were treated but were still in serious condition achieved hematological complete remission after receiving 300mg of dosed medicines. After one and a half years of treatment, the patient's progression-free survival rate is still as high as 89.2%. In addition, it can effectively prolong the patient's survival. Initially, only 30% of patients diagnosed with CML survived five years. Imatinib price plays major role in CLL patients life.